Novel Agents in Systemic Lupus Erythematosus (AstraZeneca’s anifrolumab) and Lupus Nephritis (Aurinia Pharmaceutical’s voclosporin and GSK’s belimumab) Introduce Paradigm Shifts
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well as several pipeline agents (including Eli Lilly’s baricitinib in SLE and Roche-Genentech’s obinutuzumab in LN) garnering high interest among rheumatologists and nephrologists November 4, 2021, EXTON, PA – After nearly a decade of stagnant innovation […]
Less Than One Year Post Launch, AbbVie’s Rinvoq Disrupts the Rheumatoid Arthritis Treatment Landscape, While a Rich Pipeline Waits in the Wings
The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global Insights EXTON, Pa., June 4, 2020 / PR Newswire / –The latest quarterly report included in Spherix’s RealTime Dynamix: Rheumatoid Arthritis (US) service captures the responses of 105 rheumatologists surveyed in May 2020 and highlights […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter
Download Report Overview EXTON, Pa., Oct. 8, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that Xeljanz’s user base has increased by a greater margin than the user base for Taltz for the treatment of psoriatic arthritis (PsA) over the last three […]
TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population
According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors, such as joint and skin efficacy, often drive the decision to switch, while non-clinical factors often influence the choice of the new brand. Download Report Overview EXTON, Pa., May 30, 2018 /PRNewswire/ — With four […]
Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights
Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market Download Report Overview EXTON, Pa., April 9, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 101 US rheumatologists reveals […]
Recent Chart Audit Reveals Switching Rheumatoid Arthritis Patients to Roche/Genentech’s RoActemra (Actemra) is Significantly More Common in the EU5 than it is in the US
EU5 adoption of Pfizer’s Xeljanz and Eli Lilly’s Olumiant has been largely limited to rheumatologists practicing in Germany, according to a recently released independent report by Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 21, 2017 /PRNewswire/ — Analysis of over 2,200 RA patients in the US and EU5 (France, Germany, Italy, Spain, and […]
Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis
From: Specialty Pharma Time By: Lauren Santye Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of […]
Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz
Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use […]
RealTime Dynamix™: Rheumatoid Arthritis US Q2
The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of biosimilars present an […]
